A prognostic model for ovarian cancer

References 28

1. 1.

   Alberts D. S., Dahlberg S., Green S. J., Garcia D., Hannigan E. V., O'Toole R., Stock-Novack D., Surwit E. A., Malviya V. K., Jolles C. J. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer. 1993;71(2 Suppl):618-627.

   Not in our library10.1002/cncr.2820710220

2. 2.

   Altman D. G., Royston P. What do we mean by validating a prognostic model? Stat Med. 2000;19(4):453-473.

   Not in our library10.1002/(sici)1097-0258(20000229)19:4<453::aid-sim350>3.0.co;2-5

3. 3.

   Ansell S. M., Rapoport B. L., Falkson G., Raats J. I., Moeken C. M. Survival determinants in patients with advanced ovarian cancer. Gynecol Oncol. 1993;50(2):215-220.

   Not in our library10.1006/gyno.1993.1195

4. 4.

   Brinkhuis M., Baak J. P., Meijer G. A., van Diest P. J., Mogensen O., Bichel P., Neijt J. P. Value of quantitative pathological variables as prognostic factors in advanced ovarian carcinoma. J Clin Pathol. 1996;49(2):142-148.

   Not in our library10.1136/jcp.49.2.142

5. 5.

   Brun J. L., Feyler A., Chêne G., Saurel J., Brun G., Hocké C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol. 2000;78(1):21-27.

   Not in our library10.1006/gyno.2000.5805

6. 6.

   Carey M.S., Dembo A.J., Simm J.E., Fyles A.W., Treger T., Bush R.S. Testing the validity of a prognostic classification in patients with surgically optimal ovarian carcinoma: a 15-year review. Int J Gynecol Cancer. 1993;3(1):24-35.

   Not in our library10.1046/j.1525-1438.1993.03010024.x

7. 7.

   Dembo A. J., Bush R. S., Brown T. C. Clinico-pathological correlates in ovarian cancer. Bull Cancer. 1982;69(3):292-297.

   Not in our library

8. 8.

   Greenland S., Finkle W. D. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol. 1995;142(12):1255-1264.

   Not in our library10.1093/oxfordjournals.aje.a117592

9. 9.

   Harrell F. E., Lee K. L., Mark D. B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-387.

   Not in our library10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4

10. 10.

    Hartmann L. C., Podratz K. C., Keeney G. L., Kamel N. A., Edmonson J. H., Grill J. P., Su J. Q., Katzmann J. A., Roche P. C. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol. 1994;12(1):64-69.

    Not in our library10.1200/jco.1994.12.1.64

11. 11.

    Högberg T., Carstensen J., Simonsen E. Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol. 1993;48(1):38-49.

    Not in our library10.1006/gyno.1993.1007

12. 12.

    Junor E. J., Hole D. J., McNulty L., Mason M., Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol. 1999;106(11):1130-1136.

    Not in our library10.1111/j.1471-0528.1999.tb08137.x

13. 13.

    Kappen H. J., Neijt J. P. Advanced ovarian cancer. Neural network analysis to predict treatment outcome. Ann Oncol. 1993;4(Suppl 4):31-34.

    Not in our library10.1093/annonc/4.suppl_4.s31

14. 14.

    Kehoe S., Powell J., Wilson S., Woodman C. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. Br J Cancer. 1994;70(5):1014-1017.

    Not in our library10.1038/bjc.1994.440

15. 15.

    Kosary C. L. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994;10(1):31-46.

    Not in our library10.1002/ssu.2980100107

16. 16.

    Lubsen J., Pool J., van der Does E. A practical device for the application of a diagnostic or prognostic function. Methods Inf Med. 1978;17(2):127-129.

    Not in our library

17. 17.

    Lund B., Williamson P. Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Ann Oncol. 1991;2(4):281-287.

    Not in our library10.1093/oxfordjournals.annonc.a057937

18. 18.

    Lund B., Williamson P., van Houwelingen H. C., Neijt J. P. Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma. Cancer Res. 1990;50(15):4626-4629.

    Not in our library

19. 19.

    Makar A. P., Baekelandt M., Tropé C. G., Kristensen G. B. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 1995;56(2):175-180.

    Not in our library10.1006/gyno.1995.1027

20. 20.

    Marsoni S., Torri V., Valsecchi M. G., Belloni C., Bianchi U., Bolis G., Bonazzi C., Colombo N., Epis A., Favalli G. Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). Br J Cancer. 1990;62(3):444-450.

    Not in our library10.1038/bjc.1990.315

21. 21.

    Marx D., Meden H., Brune T., Kron M., Korabiowska M., Kuhn W., Schauer A. Mib-1 evaluated proliferative activity in ovarian cancer with respect to prognostic significance. Anticancer Res. 1997;17(1B):775-780.

    Not in our library

22. 22.

    Meden H., Marx D., Raab T., Kron M., Schauer A., Kuhn W. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. J Obstet Gynaecol (Tokyo 1995). 1995;21(2):167-178.

    Not in our library10.1111/j.1447-0756.1995.tb01090.x

23. 23.

    Nagele F., Petru E., Medl M., Kainz C., Graf A. H., Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1995;86(2):259-264.

    Not in our library10.1016/0029-7844(95)00126-c

24. 24.

    Peters-Engl C., Obermair A., Heinzl H., Buxbaum P., Sevelda P., Medl M. CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer. 1999;81(4):662-666.

    Not in our library10.1038/sj.bjc.6690744

25. 25.

    Swenerton K. D., Hislop T. G., Spinelli J., LeRiche J. C., Yang N., Boyes D. A. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol. 1985;65(2):264-270.

    Not in our library

26. 26.

    Warwick J., Kehoe S., Earl H., Luesley D., Redman C., Chan K. K. Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. Br J Cancer. 1995;72(6):1513-1517.

    Not in our library10.1038/bjc.1995.539

27. 27.

    van Buuren S., Boshuizen H. C., Knook D. L. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18(6):681-694.

    Not in our library10.1002/(sici)1097-0258(19990330)18:6<681::aid-sim71>3.0.co;2-r

28. 28.

    van Houwelingen J. C., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Neijt J. P. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol. 1989;7(6):769-773.

    Not in our library10.1200/jco.1989.7.6.769

Cited by papers we hold 6

• Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature · 2010
  No notice
• Comparison of imputation methods for handling missing covariate data when fitting a Cox proportional hazards model: a resampling study · 2010
  No notice
• Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines · 2009
  No notice
• Survival Analysis Part I: Basic concepts and first analyses · 2003
  No notice
• Survival Analysis Part II: Multivariate data analysis – an introduction to concepts and methods · 2003
  No notice
• Survival Analysis Part IV: Further concepts and methods in survival analysis · 2003
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.